» Articles » PMID: 7927938

Enhanced Expression of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) in the Stroma of Breast Carcinomas Correlates with Tumor Recurrence

Overview
Journal Int J Cancer
Specialty Oncology
Date 1994 Nov 1
PMID 7927938
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The 72-kDa (MMP-2, gelatinase A) and the 92-kDa (MMP-9, gelatinase B) matrix metalloproteinases have been associated with tumor cell invasion and metastasis. Immunohistological staining of MMP-2 and MMP-9, basal lamina collagen IV and TIMP-2 were performed on frozen sections of 83 invasive breast carcinomas. MMP-2 and MMP-9 were associated with neoplastic cell plasma membrane in 72% of cases and exhibited inter-tumoral variability of staining intensity. MMP-2 and MMP-9 staining was not correlated with presence of metastases at time of diagnosis or with disease outcome. TIMP-2 was detected in the peri-tumoral stroma and was present in 87% of cases. Residual benign breast tissue was negative for TIMP-2 staining. Neoplasms with diffuse TIMP-2 staining (24%) recurred significantly more frequently (75% recurred) than cases with focal (42% recurred) or absent (27% recurred) TIMP-2. Presence of collagen IV was negatively correlated with gelatinase staining. We conclude that up-regulation of MMP-2 and MMP-9 expression in breast tumor cells is reciprocally correlated to collagen IV staining. Clinical outcome, however, is more closely related to the presence of TIMP-2 than the corresponding MMPs. Enhanced TIMP-2 expression, therefore, may denote a stromal response to tumor invasion, indicative of aggressive behavior in a subset of breast carcinomas.

Citing Articles

TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer.

Zhang G, Luo X, Wang Z, Xu J, Zhang W, Chen E Aging (Albany NY). 2022; 14(1):297-315.

PMID: 35022331 PMC: 8791226. DOI: 10.18632/aging.203793.


May High MMP-2 and TIMP-2 Expressions Increase or Decrease the Aggressivity of Oral Cancer?.

Shrestha B, Bajracharya D, Byatnal A, Kamath A, Radhakrishnan R Pathol Oncol Res. 2016; 23(1):197-206.

PMID: 27853937 DOI: 10.1007/s12253-016-0149-3.


Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells.

Cepeda M, Pelling J, Evered C, Williams K, Freedman Z, Stan I Mol Cancer. 2016; 15(1):65.

PMID: 27756325 PMC: 5070195. DOI: 10.1186/s12943-016-0547-x.


TIMP-2 Interaction with MT1-MMP Activates the AKT Pathway and Protects Tumor Cells from Apoptosis.

Valacca C, Tassone E, Mignatti P PLoS One. 2015; 10(9):e0136797.

PMID: 26331622 PMC: 4558019. DOI: 10.1371/journal.pone.0136797.


Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.

Lacerda L, Faria A, Fontana V, Moreno H, Sandrim V Arq Bras Cardiol. 2015; 105(2):168-75.

PMID: 26039662 PMC: 4559126. DOI: 10.5935/abc.20150060.